Researchers uncover 'hidden key' to immunotherapy for intractable brain tumors

Researchers person uncovered a hint to wherefore immune checkpoint inhibitors—cancer therapies that merchandise the immune "brakes" exploited by tumors to evade attack—show constricted efficacy successful immoderate encephalon tumors. A KAIST probe squad recovered that B-cell and antibody responses initiated successful tumor-draining lymph nodes, alternatively than T cells alone, are captious to the antitumor effects of anti-CTLA-4 therapy, opening a caller avenue for treating intractable encephalon tumors.